Table 3.
Mean post-treatment Visual Analogue Scale (VAS) scores in the Autologous Conditioned Serum (ACS), ACS+Cortisone (ACS+C), and ACS+C+recombinant IL-1 receptor antagonist protein (ACS+C+rIRAP) groups after controlling for the pre-treatment VAS scores.
| Total | Post hoc | Mild OA | Post hoc | Severe OA | Post hoc | ||||
|---|---|---|---|---|---|---|---|---|---|
| Overall | N=150 | 3.15±0.22 | N=96 | 3.05±0.30 | N=54 | 3.31±0.33 | |||
| ACS | N=62 | 2.83±0.29 | N=46 | 2.90±0.34 | N=6 | 2.54±0.54 | |||
| ACS+C | N=71 | 3.70±0.27 | N=41 | 3.23+0.36 | N=30 | 4.31±0.40 | |||
| ACS+C+rlRAP | N=17 | 2.92±0.54 | N=9 | 3.01±0.76 | N=8 | 3.09±0.75 | |||
| P | 0.09 | - | 0.81 | - | N=54 | <0.05 | ACS <ACS+C | ||
| Effect size (ɳ2) | 0.03 | <0.01 | 0.12 | ||||||
| Power (1-β) | 0.49 | 0.08 | 0.62 | ||||||
N, number of hips; OA, osteoarthritis; Mild, Kellgren/Lawrence (K/L) hip grade 2-3; Severe, K/L hip grade 4; VAS, Visual Analogue Scale (0=no pain, 10=most severe pain). The figures represent M±SE, P values were calculated by analysis of covariance using the pre-treatment VAS scores as a covariate with the effect size ɳ2 (≥0.14=large, ≥0.06=moderate, ≥0.01=small) and Bonferroni-corrected post hoc tests. Power ≥0.80=large.